{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:33:55Z","timestamp":1789583635365,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.labinv.2026.106135","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:46:09Z","timestamp":1779205569000},"page":"106135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paired Tissue and Circulating Tumor DNA Profiling Reveals Novel ESR1 Amplifications and CDK4\/6 Inhibitor Resistance Mechanisms in Hormone Receptor\u2013Positive\/HER2\u2013Negative Metastatic Breast Cancers"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5329-4666","authenticated-orcid":false,"given":"Liu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-5579","authenticated-orcid":false,"given":"Yihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2026.106135_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100146","article-title":"Liquid biopsy into the clinics: current evidence and future perspectives","volume":"4","author":"Boukovala","year":"2024","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.labinv.2026.106135_bib2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jmoldx.2025.05.007","article-title":"Cell-free DNA, tumor molecular concordance, and clinical correlates of patients with cancer treated in a large community health care network","volume":"27","author":"LaFramboise","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.labinv.2026.106135_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106135_bib5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib7","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5858\/134.6.907","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.labinv.2026.106135_bib8","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.labinv.2026.106135_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.labinv.2026.106135_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2026.106135_bib11","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer","volume":"393","author":"Campone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106135_bib12","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106135_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.labinv.2026.106135_bib14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41416-024-02804-6","article-title":"Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4\/6 inhibitors","volume":"131","author":"Sablin","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.labinv.2026.106135_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e12567","article-title":"Tumor copy number alterations were associated with primary endocrine resistance in ER+ breast cancer","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010563","article-title":"ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing hormone receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)","volume":"19","author":"Ferrando","year":"2023","journal-title":"PLoS Genet"},{"key":"10.1016\/j.labinv.2026.106135_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1516409","article-title":"A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer","volume":"19","author":"Mahdi Khamaneh","year":"2025","journal-title":"Oncol Rev"},{"key":"10.1016\/j.labinv.2026.106135_bib18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103731","article-title":"Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations","volume":"9","author":"Boscolo Bielo","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.labinv.2026.106135_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-022-00390-5","article-title":"Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib","volume":"8","author":"Shishido","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.labinv.2026.106135_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10549-022-06637-w","article-title":"PIK3CA-mutations in breast cancer","volume":"196","author":"Reinhardt","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.labinv.2026.106135_bib22","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.labinv.2026.106135_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.31722","article-title":"Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis","volume":"7","author":"Dickinson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.labinv.2026.106135_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.annonc.2024.09.010","article-title":"Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials","volume":"36","author":"Andre","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib25","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/1078-0432.CCR-22-3573","article-title":"Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer","volume":"30","author":"Goetz","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2026.106135_bib26","article-title":"Circulating tumor DNA genotyping of intrinsic and acquired gene alterations in patients with advanced breast cancer receiving palbociclib: biomarker results from POLARIS study","volume":"9","author":"Tripathy","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.labinv.2026.106135_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683726000656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:33:20Z","timestamp":1784028800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683726000656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0023683726000656"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106135","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paired Tissue and Circulating Tumor DNA Profiling Reveals Novel ESR1 Amplifications and CDK4\/6 Inhibitor Resistance Mechanisms in Hormone Receptor\u2013Positive\/HER2\u2013Negative Metastatic Breast Cancers","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2026.106135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"106135"}}